Paper40972018
Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma.
Wittling MC and 9 others. J Immunol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma. Papers, record 40972018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40972018
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Cholangiocarcinoma | Major topic |
| Bile Duct Neoplasms | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Animals | |
| Mice | |
| Disease Models, Animal | |
| Cell Line, Tumor | |
| Humans | |
| Antigens, Neoplasm | |
| Female | |
| CD3 Complex | |
| Mice, Inbred C57BL |
Source PubMed
Grants29
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21CA270903 | NCI NIH HHS | United States | R21CA270903 | PubMed | NIH RePORTER |
| R01 CA208514 | NCI NIH HHS | United States | R01CA208514 | PubMed | NIH RePORTER |
| 1F30CA291027-01A1 | NCI NIH HHS | United States | F30CA291027 | PubMed | NIH RePORTER |
| TL1 TR002382 | NCATS NIH HHS | United States | TL1TR002382 | PubMed | NIH RePORTER |
| R01CA275199 | NCI NIH HHS | United States | R01CA275199 | PubMed | NIH RePORTER |
| TL1TR002382 | NIH HHS | United States | TL1TR002382 | PubMed | NIH RePORTER |
| F30 CA291027 | NCI NIH HHS | United States | F30CA291027 | PubMed | NIH RePORTER |
| R21 CA266088 | NCI NIH HHS | United States | R21CA266088 | PubMed | NIH RePORTER |
| V Foundation and Emory University | PubMed | PubMed | |||
| UL1 TR002378 | NCATS NIH HHS | United States | UL1TR002378 | PubMed | NIH RePORTER |
| NIH HHS | United States | PubMed | PubMed | ||
| T32 CA272392-01A1 | NCI NIH HHS | United States | T32CA272392 | PubMed | NIH RePORTER |
| Cholangiocarcinoma Foundation | PubMed | PubMed | |||
| R01 CA275199 | NCI NIH HHS | United States | R01CA275199 | PubMed | NIH RePORTER |
| R01 CA228406 | NCI NIH HHS | United States | R01CA228406 | PubMed | NIH RePORTER |
| R21 CA270903 | NCI NIH HHS | United States | R21CA270903 | PubMed | NIH RePORTER |
| R01CA228406 | NCI NIH HHS | United States | R01CA228406 | PubMed | NIH RePORTER |
| UL1TR002378 | NIH HHS | United States | UL1TR002378 | PubMed | NIH RePORTER |
| Abraham and Phyllis Katz Foundation | PubMed | PubMed | |||
| R01CA208514 | NCI NIH HHS | United States | R01CA208514 | PubMed | NIH RePORTER |
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12242449 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. | Science | 2002 | https://conductscience.org/library/papers/12242449 | PubMed |
| 2 | 38550594 | Adoptive T cell therapy for solid tumors: current landscape and future challenges. | Front Immunol | 2024 | https://conductscience.org/library/papers/38550594 | PubMed |
| 3 | 32008328 | Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). | Chin Clin Oncol | 2020 | https://conductscience.org/library/papers/32008328 | PubMed |
| 4 | 24812403 | Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. | Science | 2014 | https://conductscience.org/library/papers/24812403 | PubMed |
| 5 | 40234732 | Publisher Correction: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40234732 | PubMed |
| 6 | 36928584 | Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36928584 | PubMed |
| 7 | 16715430 | Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. | Surg Today | 2006 | https://conductscience.org/library/papers/16715430 | PubMed |
| 8 | 38625642 | Lifileucel: First Approval. | Mol Diagn Ther | 2024 | https://conductscience.org/library/papers/38625642 | PubMed |
| 9 | 15980149 | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15980149 | PubMed |
| 10 | 28522749 | Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. | Cancer Res | 2017 | https://conductscience.org/library/papers/28522749 | PubMed |
| 11 | 22745104 | Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22745104 | PubMed |
| 12 | 31207604 | TOX is a critical regulator of tumour-specific T cell differentiation. | Nature | 2019 | https://conductscience.org/library/papers/31207604 | PubMed |
| 13 | 25428507 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. | Nature | 2014 | https://conductscience.org/library/papers/25428507 | PubMed |
| 14 | 38458319 | Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. | J Hepatol | 2024 | https://conductscience.org/library/papers/38458319 | PubMed |
| 15 | 39199630 | Strategies for Improving CAR T Cell Persistence in Solid Tumors. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39199630 | PubMed |
| 16 | 33276030 | CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. | J Hepatol | 2021 | https://conductscience.org/library/papers/33276030 | PubMed |
| 17 | 34408920 | Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. | Oncoimmunology | 2021 | https://conductscience.org/library/papers/34408920 | PubMed |
| 18 | 37722960 | Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment. | Dig Liver Dis | 2024 | https://conductscience.org/library/papers/37722960 | PubMed |
| 19 | 38816232 | Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/38816232 | PubMed |
| 20 | 33128876 | Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. | Immunity | 2020 | https://conductscience.org/library/papers/33128876 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41822509 | Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/41822509 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40972018
GET https://conductscience.org/api/papers/v1/40972018/grants?page=2